tetano
Editor, Senior Moderator
Transpl Infect Dis. 2015 Mar 2. doi: 10.1111/tid.12355. [Epub ahead of print]
[h=1]Impact of squalene-based adjuvanted influenza vaccination on graft outcome in kidney transplant recipients.[/h] Fern?ndez-Ruiz M[SUP]1[/SUP], Lumbreras C, Arrazola MP, L?pez-Medrano F, Andr?s A, Morales JM, de Juanes JR, Aguado JM.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Safety concerns have been raised about the use of adjuvanted vaccines after kidney transplantation.
[h=4]METHODS:[/h] We retrospectively analyzed 65 kidney transplant (KT) recipients who received ≥1 dose of influenza vaccine (pandemic or seasonal) during the 2009-2010 campaign. Participants were classified into 2 groups: those who received a squalene-based AS03- or MF59-adjuvanted vaccine ("adjuvanted vaccination" [AV] group, n = 37) and those who exclusively received non-adjuvanted vaccines ("non-adjuvanted vaccination" [NAV] group, n = 28). Primary outcomes included occurrence of biopsy-proven acute graft rejection (BPAR) and graft function at months 6 and 12 after vaccination. Patients were followed up until graft loss, death, or October 2010.
[h=4]RESULTS:[/h] Four episodes of BPAR occurred during post-vaccination follow-up, with no differences between the AV and NAV groups, in terms of cumulative incidence (5.4% vs. 7.1%, respectively; P = 0.581), incidence rate (0.22 vs. 0.18 episodes per 1000 transplant-days; P = 0.950), or occurrence of severe episodes (T-cell-mediated BPAR of grade ≥2a) (2.7% vs. 3.6%; P = 0.680). No between-group differences were seen in graft function after vaccination.
[h=4]CONCLUSION:[/h] Adjuvanted influenza vaccination in KT recipients seems to be safe regarding graft outcome.
? 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
[h=4]KEYWORDS:[/h] adjuvanted vaccine; graft rejection; influenza vaccination; kidney transplantation; safety.
PMID: 25728936 [PubMed - as supplied by publisher]
[h=1]Impact of squalene-based adjuvanted influenza vaccination on graft outcome in kidney transplant recipients.[/h] Fern?ndez-Ruiz M[SUP]1[/SUP], Lumbreras C, Arrazola MP, L?pez-Medrano F, Andr?s A, Morales JM, de Juanes JR, Aguado JM.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Safety concerns have been raised about the use of adjuvanted vaccines after kidney transplantation.
[h=4]METHODS:[/h] We retrospectively analyzed 65 kidney transplant (KT) recipients who received ≥1 dose of influenza vaccine (pandemic or seasonal) during the 2009-2010 campaign. Participants were classified into 2 groups: those who received a squalene-based AS03- or MF59-adjuvanted vaccine ("adjuvanted vaccination" [AV] group, n = 37) and those who exclusively received non-adjuvanted vaccines ("non-adjuvanted vaccination" [NAV] group, n = 28). Primary outcomes included occurrence of biopsy-proven acute graft rejection (BPAR) and graft function at months 6 and 12 after vaccination. Patients were followed up until graft loss, death, or October 2010.
[h=4]RESULTS:[/h] Four episodes of BPAR occurred during post-vaccination follow-up, with no differences between the AV and NAV groups, in terms of cumulative incidence (5.4% vs. 7.1%, respectively; P = 0.581), incidence rate (0.22 vs. 0.18 episodes per 1000 transplant-days; P = 0.950), or occurrence of severe episodes (T-cell-mediated BPAR of grade ≥2a) (2.7% vs. 3.6%; P = 0.680). No between-group differences were seen in graft function after vaccination.
[h=4]CONCLUSION:[/h] Adjuvanted influenza vaccination in KT recipients seems to be safe regarding graft outcome.
? 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
[h=4]KEYWORDS:[/h] adjuvanted vaccine; graft rejection; influenza vaccination; kidney transplantation; safety.
PMID: 25728936 [PubMed - as supplied by publisher]